Taewoong Medical

What Taewoong Medical does

Taewoong Medical Co., Ltd. is a South Korea-based medical device manufacturer founded in 1991, specializing in self-expandable metallic stents (SEMS) and therapeutic endoscopy devices built on proprietary nitinol shape memory alloy wire technology. The company organizes its portfolio into three verticals: Gastroenterology (the Niti-S stent platform spanning EUS, biliary, pancreatic, esophageal, duodenal, and colonic variants, plus lumen-apposing stents SPAXUS and NAGI, the KAFFES intraductal biliary stent, and the BETA bariatric stent), Cardiology (the PULSTA transcatheter pulmonary valve developed with Seoul National University Hospital), and Endoscopes (the in-development Optimos modular system with detachable insertion tubes). It also markets endoscopic RFA devices (ELRA, EUSRA, VIVA Combo) for biliary and pancreatic tumor ablation, plus accessories such as guidewires and cystotomes.

The business operates a B2B hardware sales model, generating revenue primarily through sale of proprietary medical devices to hospitals, specialty gastroenterology and cardiology clinics, diagnostic centers, and emergency ambulatory facilities. Distribution combines direct sales (via the TaeWoong USA subsidiary established in 2014), exclusive international distributor relationships spanning 79 countries, and channel partnerships with Cook Medical (U.S., from 2018) and, following the January 2024 acquisition, Olympus Corporation (global GI EndoTherapy portfolio). Pricing is not publicly disclosed and is set through B2B channels. Marketing emphasizes clinical evidence generation through peer-reviewed publications, key opinion leader training programs (notably the EUS-RFA Master Course), and presence at major international congresses (DDW, ESGE, UEGW, APDW). Following Olympus's approximately $370 million acquisition (announced January 2024, completed March 2025), Taewoong operates as a wholly-owned subsidiary with its product portfolio integrated into Olympus's global distribution infrastructure, while continuing to pursue independent regulatory milestones such as the 2026 FDA 510(k) clearance for SPAXUS and CE MDR Class III certification for PULSTA.

Name

Taewoong Medical

Legal name

Taewoong Medical Co., Ltd.

Website

https://taewoongmedical.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Taewoong Medical is a South Korean medical device manufacturer founded in 1991, specializing in nitinol-based self-expandable metallic stents, endoscopic RFA devices, and the PULSTA pulmonary valve for gastroenterology and cardiology hospitals, distributed globally across 79 countries and now operating as an Olympus subsidiary.

Ownership category

akta.pro rank

Product category

Interventional Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

akta.pro secondary industries

Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB), Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM)

Keywords

• Gastrointestinal stents
• Self-expandable stents
• Endoscopic ablation devices
• Transcatheter pulmonary valves
• Interventional endoscopy devices

Headquarters

HQ city

Kimpo

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Taewoong Medical generates revenue through the sale of proprietary medical devices including self-expandable metallic stents (gastrointestinal, biliary, esophageal, duodenal, colonic, pancreatic, EUS stents), endoscopic RFA devices (ELRA, EUSRA, VIVA Combo), endoscopic accessories (guidewires, cystotomes), cardiac valves (PULSTA), and endoscopes (Optimos). The company operates through direct sales operations (e.g., TaeWoong USA), distributor agreements, and partnership arrangements.
2. Technology Licensing and Distribution Partnerships: Following the acquisition by Olympus Corporation in January 2024, Taewoong's products are distributed through Olympus's global GI EndoTherapy portfolio. Prior to the acquisition, Cook Medical distributed selected Taewoong stents in the U.S. market.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Taewoong Medical designs, manufactures, and globally distributes proprietary medical devices for minimally invasive procedures. Its core portfolio includes the Niti-S self-expandable metallic stent (SEMS) platform with SPAXUS, NAGI, KAFFES, BETA, and HOT SPAXUS variants for gastrointestinal applications, the UVENTA silicone-covered ureteral stent for urology, endoscopic radiofrequency ablation (RFA) devices (ELRA, EUSRA, VIVA Combo), the PULSTA transcatheter pulmonary valve for cardiology, and the Optimos modular endoscope system, plus guidewires and cystotome accessories.

Product overview

Taewoong Medical is a medical device manufacturer specializing in self-expandable metallic stents and therapeutic endoscopy devices. The company offers a comprehensive portfolio organized into three main categories: Gastroenterology (including Niti-S™ stent platform with multiple variants like SPAXUS™, NAGI™, KAFFES™, BETA™; and Endoscopic RFA products including ELRA™, EUSRA™, VIVA Combo™), Cardiology (PULSTA™ pulmonary valve), and Endoscopes (Optimos™ system). The product lines serve minimally invasive procedures for digestive and cardiac conditions, with global presence across 79 countries. Key products include lumen-apposing stents for EUS-guided drainage, biliary stents, esophageal stents, RFA ablation probes, and cardiac valves.

Differentiator

Problem solved

Functional benefit

Brands

• Niti-S: Self-expandable metallic stent product line including SPAXUS, NAGI, KAFFES, and other stent variants
• ELRA
• EUSRA
• VIVA Combo
• PULSTA
• UVENTA
• Optimos

Products and services

• Niti-S Stent Platform Proprietary family of self-expandable metallic stents built on nitinol shape memory alloy, with multiple diameter/length/geometry variants designed for gastrointestinal strictures, biliary drainage, and EUS-guided transmural drainage procedures. Targeted at interventional gastroenterologists performing therapeutic endoscopy in hospitals and specialty centers.
• Niti-S SPAXUS Stent Dual-design stent within the Niti-S platform intended for gastrointestinal stricture management and EUS-guided drainage procedures. Distributed to hospitals and endoscopy centers globally.
• Niti-S NAGI Stent

Quantifiable outcome

• SPAXUS Stent demonstrated 97.1% clinical success rate in treating pancreatic pseudocysts with zero device-related serious adverse events (FDA 510(k) clinical data)
• +6 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Olympus CorporationcoreStrategic or Co-development Partner · 1 January 2024Olympus Corporation acquired Taewoong Medical in January 2024 for approximately $370 million, completing the deal after regulatory approval. The acquisition is designed to expand Olympus's GI EndoTherapy product portfolio and enhance its global presence in minimally invasive medical solutions. The transaction aims to improve patient outcomes by integrating Taewoong Medical's innovative devices and expertise into Olympus's offerings. Taewoong's products are now distributed through Olympus's global network.
• Cook MedicalcoreChannel Partner/ Reseller/ Distributor · 4 June 2018Cook Medical partnered with Taewoong Medical in June 2018 to distribute a selection of stents into the U.S. market, beginning November 1, 2018. The partnership included the Niti-S Through the Scope (TTS) Esophageal Stent (preloaded in a 10.5 Fr delivery system), the Niti-S S Esophageal Stent, and the Niti-S Biliary Stent. The announcement at DDW 2018 marked the start of a new era for both partners and customers in the U.S. market.
• Asan Medical CenterminorImplementation/ SI/ Consulting Partner · 6 January 2017Asan Medical Center directed the 2nd EUS-guided RFA Master Course Program (AERAT) in Seoul, Korea from January 6-7, 2017. Prof. Dong Wan Seo served as director, delivering lectures on EUS-procedure cases and providing hands-on sessions at the animal laboratory with phantom and porcine models. Taewoong Medical participated with its EUSRA probe product.
• KSGE (Korea Society of Gastrointestinal Endoscopy)minorImplementation/ SI/ Consulting Partner · 1 January 2017Taewoong Medical supported a hands-on training program organized by KSGE at the ENDO 2017 conference in Hyderabad, India. KSGE provided metal stenting training to over 40 participants with 6 stations covering esophagus, pylorus, colon, bile duct, CBD metal stenting, and hilar bile duct procedures.
• TAGE (Thai Association of Gastrointestinal Endoscopy)minorImplementation/ SI/ Consulting Partner · 1 January 2017Taewoong Medical supported a hands-on training program organized by TAGE at the ENDO 2017 conference in Hyderabad, India. TAGE provided EUS-guided drainage training including fine needle aspiration, EUS biliary drainage with metal stent, and EUS pseudocyst drainage with NAGI and SPAXUS stents.
• Nord Hospital (Marseille, France)minorImplementation/ SI/ Consulting Partner · 1 January 2017Nord Hospital in Marseille, France served as a co-host venue for Taewoong Medical's EUS-guided RFA Master Course Program, directed by Prof. Marc Barthet. The program combined lectures, patient case observation, and hands-on sessions for EUS-guided RFA technique training.
• Seoul National University Hospital (SNUH)coreStrategic or Co-development Partner · 1 January 2014SNUH and TaeWoong Medical collaborated since 2014 on the development of the PULSTA pulmonary valve. The research team, led by Professors Kim Ki-bum, Kim Yong-jin, and Im Heung-gook, developed artificial heart valves using pig and bovine adrenal glands along with a stent not requiring open chest surgery. SNUH received sales approval from the Ministry of Food and Drug Safety for the pulmonary artery artificial heart valve. Taewoong Medical's PULSTA received CE MDR Class III certification in January 2026.
• Euromedical (Italian/Cuban Distributor)minorChannel Partner/ Reseller/ Distributor · 12 July 2013Euromedical, Taewoong Medical's Italian/Cuban distributor, collaborated to organize the 2nd Workshop of Advanced GI Stent Training at the National Center of Minimal Access Surgery in Havana, Cuba (July 12-13, 2013). Approximately 50-60 doctors from Mexico, Canada, Switzerland, and Cuba attended, with live demonstration cases conducted by Dr. Massimo Conio and Dr. Guido Costamagna.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Boston Scientific: Boston Scientific is a global leader in endoscopy and GI intervention, offering a broad portfolio of biliary, esophageal, and colonic stents, along with EUS accessories. Taewoong's Niti-S SPAXUS, NAGI, and KAFFES compete directly with Boston Scientific's lumen-apposing and biliary stent lines, serving the same gastroenterology hospital customers.
• Medtronic: Medtronic is a dominant player in GI endoscopy, interventional pulmonology, and structural heart (including the Melody transcatheter pulmonary valve, a direct PULSTA competitor). Taewoong's Niti-S portfolio and PULSTA both compete for hospital contracts that Medtronic's broader salesforce typically controls.
• Olympus Corporation: Olympus is Taewoong's parent company (acquired January 2024) and the global leader in flexible endoscopy systems and GI EndoTherapy devices. While now the acquirer, Olympus's own GI stent and EUS accessory portfolio overlaps directly with Taewoong's products, making it both a parent and a same-space competitor.
• Fujifilm Healthcare: Fujifilm is one of the three major endoscopy system manufacturers (alongside Olympus and Pentax). Its endoscopy division competes with Taewoong's Optimos platform for hospital visualization contracts, and Fujifilm also offers complementary therapeutic endoscopy devices that overlap with Taewoong's GI stent franchise.
• Pentax Medical (HOYA Corporation): Pentax Medical is a leading global endoscope manufacturer with a portfolio spanning flexible endoscopy systems used in GI, ENT, and pulmonology. As Optimos enters the market, Pentax represents one of three entrenched incumbents Taewoong must displace or differentiate against in hospital endoscopy rooms.
• Merit Medical Systems: Merit Medical manufactures a broad portfolio of disposable medical devices including esophageal and biliary stents, with significant global distribution. It competes with Taewoong in GI intervention and shares similar hospital call points in gastroenterology, interventional radiology, and endoscopy suites.
• Edwards Lifesciences: Edwards Lifesciences is the dominant structural heart company with the SAPIEN transcatheter heart valve platform, including off-label and indication-specific use for pulmonary valve replacement. PULSTA's CE MDR certification places it in competitive context with Edwards' congenital heart programs across European centers.

Direct peers

• Cook Medical: Cook Medical has been Taewoong's U.S. distribution partner since 2018 for selected esophageal and biliary stents, while also manufacturing its own competitive GI stent portfolio. The two companies operate as both partners and direct competitors in the GI endoscopy space, targeting the same hospital call points.
• Micro-Tech (Nanjing) Co., Ltd. Micro-Tech is a Chinese medical device manufacturer with a comprehensive GI endoscopy portfolio including biliary, esophageal, and EUS-guided stents. It is one of the closest direct competitors to Taewoong in the global self-expandable metallic stent market, particularly in Asia, Europe, and emerging markets.
• M.I. Tech Co., Ltd. M.I. Tech is a Korean medical device company specializing in GI stents, including the HANAROSTENT self-expandable metallic stent line. As a fellow Korean-headquartered competitor, M.I. Tech directly overlaps with Taewoong's Niti-S portfolio across similar gastroenterology and pulmonology use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/taewoongmedical
• YouTubeyoutube.com/channel/UCynDCm_78fa-EzBrfPf_aoQ
• Facebookfacebook.com/taewoongmedical
• LinkedInlinkedin.com/company/taewoongmedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taewoong Medical